The following commercial antibodies were used in this study: anti‐Nup62 (rabbit; Invitrogen, PA5‐21882), anti‐CKAP4/Climp63 (rabbit; Proteintech, 16686‐1‐AP; Fig 2), anti‐Calnexin (rabbit; Abcam, ab22595), anti‐Climp63 (mouse; Enzo lifesciences, ALX‐804‐604; Figs 5 and EV2), anti‐CREST (human; ImmunoVision, HCT‐0100), anti‐phospho‐Histone H3(S10) (rabbit; Cell Signaling Technology, 9701S), anti‐RTN4/NOGO (rabbit; Proteintech, 10950‐1‐AP), and anti‐POM121 (rabbit; ThermoFisher Scientific, PA5‐85161). Rabbit antibodies against GP210, Nup160, Nup133, Nup107, Nup96, Nup53 and Nup214 have been previously described (Mansfeld et al, 2006 (link); Laurell et al, 2011 (link); Linder et al, 2017 (link)).